|
|
|
|
|
Sessions of Interest for the Upcoming 2021 Annual Meeting
|
|
|
|
|
Plenary- Sunday - June 6th
|
|
|
|
Pembrolizumab versus placebo as post-nephrectomy adjuvant therapy for patients with renal cell carcinoma: Randomized, double-blind, phase III KEYNOTE-564 study.
Presented By: Toni Choueiri, MD
|
|
|
|
|
|
|
|
|
|
|
|
Discussion "Pembrolizumab versus placebo as post-nephrectomy adjuvant therapy for patients with renal cell carcinoma: Randomized, double-blind, phase III KEYNOTE-564 study.
Presented By: Rana McKay, MD
|
|
|
|
|
|
|
|
|
|
|
|
Phase III study of lutetium-177-PSMA-617 in patients with metastatic castration-resistant prostate cancer (VISION).
Presented By: Michael Morris, MD
|
|
|
|
|
|
|
|
|
|
|
|
Discussion: (VISION) Phase III study of lutetium-177-PSMA-617 in patients with metastatic castration-resistant prostate cancer.
Presented By: Mary-Ellen Taplin, MD, FASCO
|
|
|
|
|
|
|
|
|
|
|
Friday - June 4th - On Demand
|
|
| Next Steps: Sequencing Therapies in Advanced Kidney Cancer in the Contemporary Era |
|
|
|
|
|
Practical Systemic Therapy Considerations After Frontline Immunotherapy Combination
Presented By: Rana R. McKay, MD
|
|
|
|
|
| Breaking Barriers: Ensuring Equity in Cancer Diagnosis, Treatment, and Trial Enrollment for Patients with Kidney and Bladder Cancers |
|
|
|
|
Women and Bladder Cancer: Ensuring the Best Care for All of Our Patients
Presented By: Jean H. Hoffman-Censits, MD
|
|
|
|
|
| Poster Session - Kidney and Bladder |
|
|
|
|
|
Outcomes of patients who progressed while receiving avelumab + axitinib (A + Ax) and received subsequent treatment (Tx) in JAVELIN Renal 101.
Presented By: Laurence Albiges, MD, Ph.D.
|
|
|
|
|
Avelumab first-line (1L) maintenance for advanced urothelial carcinoma (UC): Analysis of clinical and genomic subgroups from the JAVELIN Bladder 100 trial.
Presented By: Thomas Powles, MD, FACP, MBBS
|
|
|
|
|
Enfortumab vedotin in cisplatin-ineligible patients with locally advanced or metastatic urothelial cancer who received prior PD-1/PD-L1 inhibitors: An updated analysis of EV-201 Cohort 2.
Presented By: Bradley McGregor, MD
|
|
|
|
|
Avelumab first-line (1L) maintenance plus best supportive care (BSC) versus BSC alone for advanced urothelial carcinoma (UC): Analysis of time to end of next-line therapy in JAVELIN Bladder 100.
Presented By: Petros Grivas, MD, Ph.D.
|
|
|
|
|
Study EV-103: Update on durability results and long term outcome of enfortumab vedotin + pembrolizumab in first line locally advanced or metastatic urothelial carcinoma (la/mUC).
Presented By: Terence W. Friedlander, MD
|
|
|
|
|
Integrating peripheral biomarker analyses from JAVELIN Renal 101: Avelumab + axitinib (A + Ax) versus sunitinib (S) in advanced renal cell carcinoma (aRCC).
Presented By: Toni K. Choueiri, MD
|
|
|
|
|
|
|
|
|
| So Your Patient With Kidney or Bladder Cancer Responded to Immunotherapy: What's Next?
|
|
|
|
|
|
Immunotherapy As Curative Therapy in Advanced Kidney and Bladder Cancer: Fantasy or Reality?
Presented By: Thomas Powles, MD, Ph.D., FCRP
|
|
|
|
|
Practical Considerations for the Treatment of Patients on Long-term Immunotherapy
Presented By: Mamta Parikh, MD, MS
|
|
|
|
|
|
|
|
|
| Oral Abstract Session - Kidney and Bladder |
|
|
|
|
|
|
|
Pembrolizumab (pembro) plus axitinib (axi) versus sunitinib as first-line therapy for advanced clear cell renal cell carcinoma (ccRCC): Results from 42-month follow-up of KEYNOTE-426
Presented By: Brian I. Rini, MD
CANTATA: Primary analysis of a global, randomized, placebo (Pbo)-controlled, double-blind trial of telaglenastat (CB-839) + cabozantinib versus Pbo + cabozantinib in advanced/metastatic renal cell carcinoma (mRCC) patients (pts) who progressed on immune checkpoint inhibitor (ICI) or anti-angiogenic therapies.
Presented By: Nizar Tannir, MD, FACP
|
|
|
|
|
|
|
|
|
|
| Health-related quality-of-life (HRQoL) analysis from the phase 3 CLEAR trial of lenvatinib (LEN) plus pembrolizumab (PEMBRO) or everolimus (EVE) versus sunitinib (SUN) for patients (pts) with advanced renal cell carcinoma (aRCC). Presented By: Robert Motzer, MD
|
|
|
|
|
Expanding VEGF Blockade Combination Therapeutic Options in Advanced Renal Cell Carcinoma
Presented By: Andrea Apolo, MD
|
|
|
|
|
Phase 2 trial of gemcitabine, cisplatin, plus nivolumab with selective bladder sparing in patients with muscle- invasive bladder cancer (MIBC): HCRN GU 16-257.
Presented By: Matt Galsky, MD
|
|
|
|
|
Pembrolizumab (pembro) in combination with gemcitabine (Gem) and concurrent hypofractionated radiation therapy (RT) as bladder sparing treatment for muscle-invasive urothelial cancer of the bladder (MIBC): A multicenter phase 2 trial.
Presented By: Arjun Balar, MD
|
|
|
|
|
Phase II trial of durvalumab plus tremelimumab with concurrent radiotherapy (RT) in patients (pts) with localized muscle invasive bladder cancer (MIBC) treated with a selective bladder preservation approach: IMMUNOPRESERVE-SOGUG trial.
Presented By: Xavier Garcia del Muro
|
|
|
|
|
Steps Toward a Bladder-Intact Cure for Muscle-Invasive Bladder Cancer
Presented By: Andrea Necchi, MD
|
|
|
|
|
A randomized phase II study comparing cisplatin and gemcitabine with or without berzosertib in patients with advanced urothelial carcinoma.
Presented By: Sumanta K. Pal, MD, FASCO
|
|
|
|
|
First-line pembrolizumab (pembro) in cisplatin-ineligible patients with advanced urothelial cancer (UC): Response and survival results up to five years from the KEYNOTE-052 phase 2 study.
Presented By: Peter H. O'Donnell, MD
|
|
|
|
|
Inducible T-cell co-stimulatory (ICOS) receptor agonist, feladilimab (fela), alone and in combination (combo) with pembrolizumab (P): Results from INDUCE-1 urothelial carcinoma (UC) expansion cohorts (ECs).
Presented By: Arjun V. Balar, MD
|
|
|
|
|
Conundrums in First-Line Urothelial Carcinoma: Is More Always Better?
Presented By: Shilpa Gupta, MD
|
|
|
|
|
|
|
|
|
| Oral Abstract Session - Prostate |
|
|
|
|
|
A phase 3 trial with a 2x2 factorial design of abiraterone acetate plus prednisone and/or local radiotherapy in men with de novo metastatic castration-sensitive prostate cancer (mCSPC): First results of PEACE-1.
Presented By: Karim Fizazi, MD, Ph.D.
|
|
|
|
|
SWOG S1216: A phase III randomized trial comparing androgen deprivation therapy (ADT) plus TAK-700 with ADT plus bicalutamide in patients (pts) with newly diagnosed metastatic hormone-sensitive prostate cancer (mHSPC) (NCT01809691).
Presented By: Neeraj Agarwal, MD
|
|
|
|
|
Decreased fracture rate by mandating bone protecting agents in the EORTC 1333/PEACEIII trial combining Ra223 with enzalutamide versus enzalutamide alone: An updated safety analysis
Presented By: Silke Gillessen, MD
|
|
|
|
|
|
|
|
